Barclays Maintains Overweight on Vir Biotechnology, Raises Price Target to $30
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Barclays analyst Etzer Darout maintains Vir Biotechnology (NASDAQ:VIR) with a Overweight and raises the price target from $26 to $30.
Barclays analyst Etzer Darout maintains Vir Biotechnology (NASDAQ:VIR) with a Overweight and raises the price target from $26 to $30.